Oncovin®
Vincristine is a vinca alkaloid that inhibits microtubule formation. Used in acute lymphoblastic leukemia, lymphomas, neuroblastoma, and other malignancies.
| Dosage Form | IV Injectable (Solution) |
| Strength | 1 mg/mL; 1 mg, 2 mg vials |
| Storage | Store at 2–8°C. Protect from light. FOR IV USE ONLY — fatal if given intrathecally. |
| Category | Oncology |
| Availability | Available for Transfer |
ALL; Hodgkin and non-Hodgkin lymphomas; rhabdomyosarcoma; neuroblastoma; Wilms tumor.
Binds to tubulin, inhibiting microtubule assembly. This arrests mitosis in metaphase and disrupts intracellular transport.
Each Burrard Pharmaceuticals technology transfer package for Vincristine includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.